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Objective: To evaluate the psychometric properties of the Taiwan Chinese Version of the EORTC QLQ-PR25
health-related quality of life (HRQOL) questionnaire for patients with prostate cancer.
Methods: 135 prostate cancer patients were recruited in the urology outpatient clinic of a university teaching
hospital. Each patient completed the EORTC QLQ-PR25 at every clinic visit between 2004 and 2008, totaling
633 assessments. Confirmatory factor analysis and Rasch analysis were used to evaluate the domain- and item-level
psychometric properties.
Results: The results supported the unidimensionality of each of the four EORTC QLQ-PR25 domains (urinary, bowel,
and hormonal-treatment-related symptoms, and sexual functioning). Item calibrations for each domain were found
invariant across the three assessment time periods. The item-person maps showed 71.3% of item coverage for the
urinary symptoms domain and 13–42.7% for the other three domains.
Conclusions: The Taiwan Chinese Version of the EORTC QLQ-PR25 questionnaire is reliable and can be used to
measure HRQOL over time. Adding new items to each domain may improve its clinical content coverage and
measurement precision.
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Prostate cancer is the most common form of cancer
among males in North America and Europe [1], and its
incidence rate has increased rapidly in Asia in the past
few years [2]. The rate rose from 1.78 per 100,000 per-
sons in 1982 to 24.55 per 100,000 persons in 2008 [3],
making prostate cancer a significant public health con-
cern in Taiwan. Although the survival time for patients
with prostate cancer has increased due to early detection
and improved treatments [4], prostate cancer related
symptoms and treatment associated side effects (e.g.,
urinary, sexual, and bowel dysfunction) have been shown* Correspondence: chchang@northwestern.edu
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reproduction in any medium, provided the orto significantly impact a patient’s health-related quality
of life (HRQOL) [4-6]. It is, therefore, important to col-
lect and use reliable and valid patient-reported HRQOL
information in order to document their responsiveness
to any specific treatments or interventions and to facili-
tate and guide clinical decisions.
Patient-reported outcomes (PROs), including HRQOL,
are becoming increasingly important in clinical research
and practice, and therefore much effort has been direc-
ted toward the development of more objective methods
of assessment [7,8]. For example, the European
Organization for Research and Treatment of Cancer
(EORTC) Quality of Life Study Group developed the
Core Questionnaire (EORTC QLQ-C30) to measure
generic aspects of HRQOL for patients with various
types of cancer. In order provide more detailed informa-
tion specific to prostate cancer, a 25-item supplementary
module, EORTC QLQ-PR25, was further developed. TheLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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questionnaire for prostate cancer patients [9-11]. It
includes four domains assessing urinary symptoms,
bowel symptoms, treatment-related symptoms, and sex-
ual activity and functioning. The results of international
field validation has been published in 2008 [9]. In Taiwan,
Chie was authorized by the EORTC to perform Chinese
translation (in traditional Chinese characters) and valid-
ation the Core Questionnaire (QLQ-C30) and its supple-
mentary modules, and their study results have been in
recent years [12-16]. But the psychometric analyses were
primarily assessed at the domain level with a small
sample size.
In this study, we used the same Taiwan Chinese Ver-
sion of the EORTC QLQ-PR25 questionnaire published
by Chie et al. in 2010 [16] to address issues relevant to
traditional psychometric analysis and small sample sizes.
We employed both confirmatory factor analysis and
Rasch analysis to thoroughly examine and understand its
psychometric properties in a larger patient population.
Rasch analysis has increasingly become popular in asses-
sing the quality of existing outcome assessment tools
and in developing new ones [17,18], as it offers a meth-
odologically rigorous way to evaluate and enhance the
measurement properties of the assessment tools [19,20].
Specifically, this study aimed to: 1) examine the stability
of item calibrations (i.e., item parameter invariance)
within each of the four domains across different time of
assessment; 2) evaluate whether the item coverage was
adequate to reliably assess the person traits along the la-
tent construct; and 3) determine whether the response




A sample of 135 prostate cancer patients treated at the
urological department of China Medical University Hos-
pital, a community-based tertiary teaching hospital in
Central Taiwan, were recruited from January 7, 2004 to
September 15, 2008. This study was approved by the In-
stitutional Review Board of the China Medical University
Hospital and all enrolled patients provided written
informed consent. Efforts were made to maximize the
patient diversity and representativeness to ensure the
generalizability of the study results in Taiwan and other
Chinese-speaking regions.
Each enrolled patient was asked to do the blood test,
biopsies and the Gleason grading system of cells at the
baseline assessment. They were also were invited to
complete the Taiwan Chinese Version of the EORTC
QLQ-C30 (Version 3.0) and the EORTC QLQ-PR25 as
well as the amount of prostate-specific antigen (PSA)
found in the gland each time during their clinical officevisit. During the study period, a total of 633 assessments
were collected from these patients at various time
points. For the purpose of psychometric evaluation,
these assessments were categorized into three groups
according to the time of assessment: (1) baseline, pre-
treatment (T0, n = 135); (2) one month post first treat-
ment (T1, n = 117); and (3) 3 months or more post
treatment (T2, n = 381; some patients completed the
EORTC QLQ-PR25 more than once).
Measure
The EORTC QLQ-PR25 is a 25-item prostate cancer
specific HRQOL questionnaire developed by the Euro-
pean Cancer Research and Treatment Organization
(EORTC). It has four domains, each with various
number of items: Urinary Symptoms (9 items; labeled
US31-US39), Bowel Symptoms (4 items; BS40-BS43),
Hormonal-treatment-related Symptoms (6 items; TS44-
TS49) and Sexual Activity and Functioning (6 items;
SX50-SX55) [9]. For this study, 5 items lacking adequate
number of responses were excluded from the analysis.
One Urinary Symptoms item that did not apply to all
patients was excluded (US38, “Has wearing an incontin-
ence aid been a problem for you? Answer this question
only if you wear an incontinence aid.”). Four follow-up
questions (SX52-SX55) to the Sexual Functioning item
(SX51, “To what extent were you sexually active?”) were
also excluded because about two-thirds of the patients
responded not being sexually active. Each of the 20
retained items was rated on a 4-point Liker-type scale
(1 = “Very much”, 2 = “Quite a bit”, 3 = “A little”, 4 =
“Not at all”). To facilitate ease of interpretation and
understanding of the analysis results, each item was
scored in the same direction, from 1 to 4, with higher
scores indicating better HRQOL (i.e., less symptomatic
or better functioning).
Data analysis
Descriptive statistics (e.g., mean, standard deviation, fre-
quency, etc.) were calculated using SPSS version 15.0
(SPSS, Inc., Chicago, Illinois) for each item. Cronbach’s
coefficient alpha was also calculated for each domain,
with a value of 0.7 or higher indicating good internal
consistency [21].
A series of confirmatory factor analysis (CFA) using
LISREL version 8.72 (Scientific Software International,
Inc.) were performed to examine the domain unidimen-
sionality. Unidimensionality, the measurement of one
underlying construct and an important pre-requisite for
Rasch analysis, was determined by the magnitude of
item factor loadings, with a value > 0.3 as an indicative of
acceptable item-domain membership. Model fits were
considered acceptable, if the goodness-of-fit index (GFI),
Bentler-Bonett normed fit index (NFI), non-normed fit
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ceed 0.9, the root mean square error of approximation
(RMSEA) values were below 0.05, and the standard root
mean-square residual (SRMR) values were below 0.08
[22,23].
Rasch Rating Scale model [24] suitable to calibrate
items with ordered response categories (e.g., “Not at all”
to “Very much”) as in the EORTC QLQ-PR25 items was
used. Item fit, item stability, coverage of item content
and person measure (item-person map), and item target-
ing were evaluated. All Rasch analyses were performed
using the Winsteps software, version 3.47 [25].Item difficulty and person measure
In Rasch measurement models, items and persons are
jointly place on the same interval-level “logit” metric. A
symptom item with a higher item difficulty value as
modeled is said to be more ‘difficult’ to not occur (i.e.,
easier to occur). A functioning item with a higher item
difficulty value, however, would be more difficult for a
person to respond with a more frequent or severe re-
sponse (e.g., “very much”) to the function or activity
described in that item. Similarly, a person with a higher
person measure is ‘more likely’ to choose a less-frequent
(e.g., “not at all”) response for a symptom but ‘more
likely’ to choose a more-frequent response (e.g., “very
much”) for performing that function or activity.Item fit
Item fit was evaluated using the infit mean-square
(denoted as Infit) statistic derived from the Rasch ana-
lysis. This goodness-of-fit statistic, defined as the ratio of
the observed to the predicted variance for an item, indi-
cates how well the item fits the rest of the items in the
same domain/scale. An item with an Infit statistic > 1.4
or < 0.7 was considered to be lack of fit according to the
Rasch model [8,23,24].Stability of item calibrations
Differential item functioning (DIF), referred to as an
item lacking item parameter or measurement equiva-
lence across different groups or settings, was identified
statistically by conducting the t-tests on the mean item
calibrations between the 3 assessment time groups
(T0 vs. T1 vs. T2). An item was said to exhibit DIF, if
the t-test statistic exceeds p < 0.016 (= 0.05 / 3) after the
Bonferroni correction for multiple testing was applied
[26,27]. Once item stability of scaling, i.e., items across
group exhibiting no DIF, was achieved, the data from all
the three groups were pooled together for subsequent
Rasch analyses to assess the item-person coverage and
other psychometric properties.Item-person map
The item-person map, where the item difficulties and
person measures were plotted together along the same
logit scale, is useful for visual inspection to identify areas
or gaps along the latent trait continuum that may be
lacking items. A logit is the natural log-odds of person
being successful at a task (e.g., answering an item cor-
rectly) versus those being unsuccessful (e.g., answering
an item incorrectly). In this study, it is a unit of meas-
urement to report relative differences between person
measure estimates and item difficulties. An item with
positive logit value indicates that the item requires a
greater level of person measure than the average (i.e.,
the item is relatively harder). A person with positive logit
value indicates that his/her person measure is greater
than the mean required level of measure for the items
(i.e., the latent trait a person possesses is greater than
the overall trait required for the tasks) [28].
Since each item was rated on a 4-point response cat-
egory (e.g., 1 = “Very much” to 4 = “Not at all” for the
frequency of symptoms or functioning), three thresholds
(each between the two adjacent response categories as
modeled) were obtained. The ordering of the three
threshold parameters for each item was examined to as-
sess model fit. It was considered to be in a non-logical
sequence when the value of threshold was not shown
from less (the first threshold) to more (the third thresh-
old) for each item [29,30].
Item coverage of the construct and ceiling or floor effect
The item coverage of the latent construct (e.g., Urinary
Symptoms) being measured was defined as the percent-
age of persons whose person measures fall between the
highest and lowest thresholds of all items in that do-
main. The ceiling effect was defined as the percentage of
people whose person measures were greater than the
highest (i.e., the third) threshold. Similarly, the floor ef-
fect is the percentage of persons whose person measures
were less than the lowest (i.e., the first) threshold
[29,31]. These three indices were used to determine how
well the items in the same scale are targeted to the per-
sons being measured [32,33].
Results
Characteristics of the study participants
The demographic and clinical characteristics of the
study participants by group (i.e., time of assessment) and
as a whole are summarized in Table 1. The mean age of
the prostate cancer patients at pre-treatment (T0) was
about 70 years. Most patients (67.2%) were in Stage II.
Surgery was the most common treatment type followed
by radiation therapy. The mean prostate-specific antigen
(PSA) values were 46.3, 10.9, and 2.8 for T0, T1, T2, re-
spectively. At T0, the mean Gleason scores were 6.59.
Table 1 Demographic and clinical characteristics of the study participants by time of assessment
Therapy period
Before therapy (T0) 1 month after therapy (T1) ≧3 months after therapy (T2) Total
(n = 135)a (n = 117)b (n = 381)c (n = 633)d
N % N % N % N %
Age Mean± SD 70.0 ± 7.6 70.4 ± 7.6 70.9 ± 7.1 70.6 ± 7.3
Median (Range) 70.1 (48.8-90.8) 70.7 (48.8-92) 70.2 (49-93) 70.2 (48.8-93)
Treatment Surgery 57 42.2 48 41.0 162 42.6 267 42.2
Irradiation 38 28.1 35 29.9 156 41.1 229 36.2
Hormone therapy 31 23.0 31 26.5 60 15.8 122 19.3
Chemical therapy 9 6.7 3 2.6 2 0.5 14 2.2
PSA Mean± SD 46.3 ± 126.9 10.9 ± 33.5 2.8 ± 16.6 12.8 ± 61.7
PSA group <=2.5 32 27.8 66 64.7 304 83.1 402 69.0
2.501-4 6 5.2 4 3.9 21 5.7 31 5.3
4.001-6 9 7.8 8 7.8 14 3.8 31 5.3
6.001-10 24 20.9 4 3.9 14 3.8 42 7.2
>10 44 38.3 20 19.6 13 3.6 77 13.2
Gleason score 2-4 17 14.2 13 12.1 53 14.9 83 14.3
5-7 70 58.3 58 54.2 203 57.2 331 56.9
> = 8 33 27.5 36 33.6 99 27.9 168 28.9
Stage I 1 0.8 1 0.9 4 1.1 6 1.0
II 84 67.2 75 67.0 276 75.8 435 72.4
III 20 16.0 21 18.8 57 15.7 98 16.3
IV 20 16.0 15 13.4 27 7.4 62 10.3
PSA, prostate-specific antigen.
a One hundred and thirty-five assessments were obtained from 135 independent subjects.
b One hundred and eleven assessments were obtained from 117 independent subjects.
c Some subjects (n = 102 subjects) responded to more than one assessment.
d A total of 633 assessments were included in the final model analysis.
Age, main type of treatment and PSA values were assessed at the same time as HRQOL questionnaire administration.
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Descriptive statistics calculated from their raw responses
and item statistics derived from the Rasch analysis are
shown in Table 2. Items in their respective domain are
listed in descending order of their mean raw scores. As
can be seen, very high percentages of patients selected
the less-frequent ‘Not at all” response (81.8% - 93.5% for
the Bowel symptom (BS) items; 52.6% - 96.0% for the
Treatment-related symptom (TS), indicating that the
majority of patients did not experience these symptoms.
In contrast, the Sexual functioning (SX) domain had
relatively high percentages (58.5% - 70.8%) of patients
choosing the “Not at all” response category, indicating
that most patients did not have sexual activity. Only the
Cronbach’s coefficients alpha of Urinary symptoms (US)
and Sexual functioning (SX) domains were above the ac-
ceptable level of 0.7.
Unidimensionality assessement
The results of CFA, after adding some covariances be-
tween error terms (3 covariance modifications for theUS domain, one covariance modification for the BS do-
main, and one covariance modification for the TS
domain), supported the assumption of unidimensionality
as the US, BS and TS domains had GFI, NFI, NNFI and
CFI values over 0.9, RMSEA and SRMR values were less
than 0.5. The unidimensionality of the 2-item SX
domain was evidenced by its Cronbach’s coefficient
alpha of 0.8.
DIF analysis for testing stability of item across groups
As can be seen in Table 2, the sequence of the mean
Rash-calibrated item difficulties was consistent across
the 3 groups, suggesting that the hierarchical structure
of the item difficulty was invariant. Moreover, the order-
ing of item difficulties (from less to more) in their re-
spective domain was also consistent between the mean
raw scores and the Rasch-derived mean item difficulties.
Among all the possible paired comparisons of item
calibrations for the three time assessment time points,
only three items were found to exhibit DIF. The US item
“Urinary incontinence” displayed significant DIF twice:
Table 2 Results of descriptive and psychometric analyses of the EORTC QLQ-PR25 by group
Raw responses (n=633) Rasch analysis
EORTC QLQ-PR25
Items ranked by difficulty
Mean score “Very Much” “Not at all” T0 T1 T2 Total DIF (P-value)
α (n=135) (n=117) (n=381) (n=633) Infit Targeting among Groups: T0, T1, T2
(SD) % % δ δ δ δ (SD) T0 vs. T1 T0 vs. T2 T1 vs. T2
Urinary symptoms (US)a 0.77 2.26
US37 Painful voiding (least frequent) 3.84(0.39) 0.0 84.5 −1.67 −2.05 −2.10 −2.00 1.23 (1.57) 0.257 0.130 0.865
US39 Limitation of activities because of US 3.67(0.62) 1.8 73.5 −1.30 −0.85 −0.98 −0.72 1.41 0.109 0.185 0.556
US35 Need to remain close to toilet 3.54(0.72) 2.6 64.3 −0.57 −0.21 −0.30 −0.37 1.08 0.147 0.208 0.633
US36 Urinary incontinence 3.53(0.63) 1.0 59.7 −0.91 −0.06 −0.23 −0.35 1.11 0.001 0.002 0.389
US34 Sleep deprivation because of US 3.25(0.82) 4.8 44.2 0.85 0.63 0.54 0.58 1.03 0.291 0.080 0.644
US31 Frequent urination in daytime 3.18(0.79) 3.4 38.7 0.87 0.80 0.83 0.78 0.86 0.753 0.815 0.884
US33 Urinary urgency 3.15(0.81) 6.1 35.7 0.97 0.78 0.94 0.87 0.93 0.347 0.845 0.347
US32 Nocturia (most frequent) 3.01(0.81) 5.3 28.1 1.49 1.09 1.27 1.22 0.79 0.044 0.172 0.278
Bowel symptoms (BS)a 0.41 3.58
BS42 Fecal blood (least frequent) 3.93(0.31) 0.3 93.5 −0.74 −0.56 −0.77 −0.71 1.27 (1.03) 0.713 0.954 0.622
BS41 Fecal incontinence 3.92(0.29) 0.0 92.6 −0.63 −1.07 −0.47 −0.63 0.98 0.384 0.689 0.172
BS40 Limitation of activities because of BS 3.82(0.45) 0.6 84.8 0.36 0.95 0.51 0.59 0.98 0.101 0.646 0.131
BS43 Bloated feeling (most frequent) 3.80(0.44) 0.5 81.8 0.94 0.50 0.74 0.74 0.95 0.206 0.490 0.421
Treatment-related symptoms (TS)a 0.41 3.32
TS45 Breast tenderness (least frequent) 3.96(0.20) 0.0 96.0 −1.95 −2.69 −1.42 −1.69 0.96 (1.22) 0.407 0.356 0.098
TS44 Hot flushes 3.89(0.34) 0.0 89.9 −0.46 −0.41 −0.68 −0.57 0.97 0.896 0.514 0.407
TS46 Swelling in legs or ankles 3.84(0.48) 1.0 87.1 0.08 0.25 −0.28 −0.09 1.27 0.599 0.202 0.048
TS48 Bothered due to weight gain 3.81(0.47) 0.6 83.9 −0.07 0.09 0.13 0.09 0.99 0.639 0.483 0.883
TS47 Bothered due to weight loss 3.78(0.51) 0.8 81.8 0.71 0.47 0.04 0.28 1.05 0.394 0.006 0.081
TS49 Felt less masculine (most frequent) 3.31(0.86) 4.9 52.6 1.73 1.76 2.11 1.98 0.97 0.858 0.033 0.045
Sexual functioning (SX)b 0.80 −6.41
SX50 Sexual interest (more likely) 1.53(0.72) 1.7 58.5 −1.11 −1.67 −1.87 −1.67 0.88 (3.97) 0.314 0.072 0.663
SX51 Sexual activity (less likely) 1.34(0.59) 1.1 70.8 1.10 1.67 1.89 1.67 0.92 0.316 0.068 0.650
Group T0: before therapy; Group T1: one month after the start of therapy; Group T2: therapy for 3 months or more; Group Total: Group T0 + T1 + T2.
a Raw responses: 1: “Very much”; 2: “Quite a bit”; 3: “A little”; 4: “Not at all”, higher score means better HRQOL/less frequent symptom.
b Raw responses: 4: “Very much”; 3: “Quite a bit”; 2: “A little”; 1: “Not at all”, higher score means better HRQOL/more interest/activity.
δ: Item difficulty, higher difficulty means worse HRQOL/more frequent symptom/problem; Targeting: the average person ability level.
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groups T0 and T2 (p= 0.002). The TS item “Bothered
due to weight loss” also displayed significant DIF be-
tween groups T0 and T2 (p= 0.006). As the DIF analysis
results supported the stability of item calibrations, it
seemed safe to combine the item response data from the
three groups (Group T0 +T1+T2) to obtain the final
calibration. The item hierarchy of the combined “Total”
group was quite similar to those of the three separate
groups (Table 2). Only one US item has a fit statistic
greater than pre-specified cut-off value of 1.4, supporting
its overall model fit.
Item-person maps
Figure 1 shows the four item-person maps, one for each
domain, depicting the person measures (upper panel)
and sets of threshold parameters (represented by the
numbers 1, 2, 3 for each item in the lower panel) jointly
positioned on the same ‘logit’ continuum ranging from
−10 to 10 using the pooled data. The average item diffi-
culty is standardized with a mean of 0 and a standard
deviation of 1. The number “1” in the lower panel indi-
cates the location at which a patient had a 50% chance
to choose either the “Quite a bit” or “Very much” re-
sponse category. Similarly, the number “2” indicates the
level at which a patient had a 50% chance to choose ei-
ther the “A little” or “Quite a bit” response category.
Thus, a patient with an estimated person measure
greater than 4 (in logit unit) in the US latent con-
tinuum would be more likely to select the “Not at all”
response category for all the Urinary Symptom items.
Inspection of the ordering of the three thresholds
revealed that, a consistent 1-2-3 (less-to-more) order
in these domains was observed, except that the Bowel
Symptoms domain had an unexpected order sequence
(2-1-3 instead of 1-2-3).
Item-person maps are used to see how well the
domain-specific items match up with the persons being
measured. As can be seen in Figure 1, person measures
were distributed more on the right side when compared
to the spread of all the item thresholds for the US, BS,
and TS domains. This suggested that items in these
domains had a greater tendency of a ceiling effect. How-
ever, different pattern was observed in the SX domain. A
high proportion of the person measures were on the left
side, suggesting a floor effect.
Coverage of the construct for person traits
The range of item thresholds and person measures
across the four domains are shown in Table 3. As can be
seen, the range of the item thresholds for the EORTC
QLQ-PR25 did not fully overlap with the range of the
person measures (coverage rate ranging from 13.0% to
73.1%). For the BS and TS domains, the coverage ratewas just 13% and 38.5%, respectively. Many patients had
person measures greater than the third threshold (87.0%
and 61.5% for BS and TS domains, respectively), suggest-
ing a significant ceiling effect (reporting no symptoms)
in these two domains. For the SX domain, the coverage
rate was 42.7%. 56.9% of the patients whose person mea-
sures were less than the lowest threshold, suggesting a
significant floor effect (reporting no interest/activity) in
the SX domain. For the US domain, the coverage rate
was 73.1%. No floor effect was found and the ceiling ef-
fect was relatively low at 26.9%.
Discussion
The results of our analyses of the Taiwan Chinese Ver-
sion of the EORTC QLQ-PR25 showed that each of the
four domains satisfied the unidimensionality assumption
and items in their respective domain had a good fit to
the Rasch model. Overall, the item hierarchy was found
to be consistent and item stability (item parameter in-
variance) was observed in all four domains across the
three time periods. The items in the US domain spread
satisfactorily along the latent trait continuum (coverage
rate, 71.3%). The significant ceiling effect in both the BS
and TS domains, as well as the noticeable floor effect in
the SX domain together suggested the inadequate item
coverage at the end in these three domains. The order-
ing of the thresholds for all the domains, except for the
BS domain, was in sequence from less to more as
intended.
Our findings of low alpha coefficients in the BS and
TS domains of the EORTC QLQ-PR25 are similar to
those have been previously reported. The EORTC official
version [9], Spanish version [10] and the Taiwan Chinese
version [16] all reported low reliability (< 0.6) and high
ceiling effects in the BS and TS domains. van Andel
et al. indicated Cronbach’s alpha coefficient reflects the
ratio of variances of the individual scale items to the
variance of the total scale. A restricted range of
responses will have a greater impact on the total scale
score than on the individual items, resulting in a lower
reliability estimate [9].
The initial development of the EORTC QLQ-PR25
items nearly 20 years ago was based on the selection
of important items by both prostate cancer patients
and clinicians. However, recent improvements in treat-
ment (e.g., three-dimensional conformal radiotherapy,
intensity-modulated radiotherapy [34]) and symptom
control for prostate cancer may have contributed to the
low symptom frequency in the items assessed in the
BS and TS domains. For example, over 90% patients
reported not having “Fecal blood”, “Fecal incontinence”
or “Breast tenderness”. In this study, the large ceiling ef-
fect (87% and 61.5% in the BS and TS domains, respect-

























































































































































































Figure 1 Person measure-item threshold map for each EORTC QLQ-PR25 domain. Logit values of the three thresholds and mean item
difficulty are represented by the numerical values 1, 2, and 3 and a diamond marker, respectively.
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Table 3 The Range of Item Thresholds and Person
Measures of the EORTC QLQ-PR25 by Domain
US BS TS SX
Item threshold -3.15−3.12 -2.26−2.27 -2.41−3.16 -7.33−8.16
Ability -2.83−5.52 -0.21−4.23 -0.10−4.72 -9.07−8.24
Cover %a 73.1 13.0 38.5 42.7
Floor effect 0.0 0.0 0.0 56.9
Ceiling effect 26.9 87.0 61.5 0.5
US, Urinary symptoms; BS, Bowel symptoms; TS, Treatment-related symptoms;
SX, Sexual functioning.
a Item threshold range covered person measure percentage.
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vant as previously selected and should be considered for
revision or even remove. More clinically relevant items
based on clinicians’ recommendations to measure the
contemporary patient's symptoms and concerns should
be developed and added. For example, items like “Diffi-
culties with bowel function” may be added to the BS do-
main and “Bone dysfunction” (osteoporosis, etc.) may be
added to the TS domain. Adding and validating new
clinically relevant and psychometrically sound items in
future studies can potentially eliminate the ceiling or
floor effect and item content gaps, and may improve the
performance of the items within the same domain.
Sexual dysfunction can occur and impact patients re-
gardless of the treatment modalities they receive [35,36],
and the time to recover from it is usually much longer
than that from other side effects. In general, about 38%
to 48% of patients had not recovered from sexual dys-
function one year after receiving treatment [6]. Although
there are six SX items in the EORTC QLQ-PR25, four of
them (SX52-SX55) are conditional and only applicable
to those being sexually active, which may lead to less
precise measurement in this domain [30]. Adding more
commonly experienced sexual functioning items, such as
the impact of “Loss of libido”, may improve it measure-
ment precision and clinical relevance. Using items from
other questionnaires, such as the 15-item version of the
International Index of Erectile Dysfunction (IIEF-15)
[37] and the Male Sexual Health Questionnaire (MSHQ)
[38], may help physicians to better measure and monitor
changes of the sexual functioning aspect of their
patients’ HRQOL.
The first two thresholds were very close to each other
but far away from the third threshold, as shown in the
item-person maps of the US and TS domains, seemed to
suggest that a binary 2-category response category may
be practical to improve readability and measurement
precision [39]. Furthermore, the issue related to the out-
of-sequence thresholds in the BS domain and the notice-
able item coverage gaps in the SX domain suggest that
further improvement is still needed. Hsueh et al.
reported that the middle categories were never the mostlikely responses of any patient and were thus redundant,
when polytomous items of index exhibited disordering
of the step difficulty. The psychometric properties of the
dichotomous items were equivalent to those of the poly-
tomous items. A scale with only dichotomous items is
much more convenient and efficient to administer [40].
Maio and Perrone pointed out that HRQOL assessment
in the elderly is complicated by several unresolved meth-
odological problems (higher frequency of illiteracy,
worse compliance with the questionnaires, concomitant
diseases, use of instruments not validated in the aged
population) [41]. A binary response category (“No” for
“Not at all” vs. “Yes” for combined “A little”, “Quite a
bit” and “Very much”) may be practically feasible to im-
prove readability and measurement precision for the Tai-
wan Chinese Version of the EORTC QLQ-PR25 and
easier to respond for prostate cancer patients, who are
typically older (70% of all prostate cancers are diagnosed
in men over the age of 70 in Taiwan) [3] and less edu-
cated (half of the patients had an education level of less
than 9 years in this study) [42].
Besides the many statistics and ways to allow for thor-
ough psychometric evaluation from the Rasch analysis in
this study, one additional strength is that our data were
from a large group of prostate cancer patients with vary-
ing levels of severity, receiving different treatment mo-
dalities and assessed at various times. As shown in
Table 2, the assessments were grouped into three groups
based on the assessment time period. The data were first
analyzed separately by time period to validate the
EORTC QLQ-PR25. The stability of item calibrations
within each domain was then compared across different
time periods. The data of these three periods were then
combined and validate again. The combined data poten-
tially maximize the patient diversity and representative-
ness to ensure the generalizability of the study results in
Taiwan. Our results showed the item stabilities held
across the three different time periods, satisfying an im-
portant measurement property for making meaningful
HRQOL score comparison for prostate cancer patients
in a longitudinal study [43].
Some limitations of this study should also be noted.
First, this study was limited in scope only to the stability
assessment across different time periods; therefore
larger-scale studies with adequate sample sizes are still
needed to examine the stability of item calibrations
across different age groups, cancer stages, and treatment
groups. Secondly, only outpatients in Central Taiwan
were sampled, which might limit its generalizability to
all Chinese-speaking prostate cancer patients in Taiwan
or other regions. Patients coming to outpatient clinics
normally are expected to have milder symptoms than
those in the inpatient settings, and may produce a higher
ceiling effect in our study. Thirdly, this study did not
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and disease stages. However, since patients with prostate
cancer often receive multiple treatment modalities and
exhibit long disease duration, our study cohort appears
to be a fair representative and therefore the results from
this pooled sample can be of practical value for clinical
implications.
Conclusions
The domain-specific items in the EORTC QLQ-PR25
were found to be unidimensional in measuring their
intended domain. The differential item functioning ana-
lysis results indicated that item calibrations were stable
across different time periods for each of the four EORTC
QLQ-PR25 domains. Adding more clinical relevant and
content appropriate items to each domain to fill the item
coverage gaps as well as to eliminate the ceiling and
floor effects would be desirable, so that the content rele-
vance and scale performance can be improved. Our sys-
tematic and thorough analysis steps to better understand
the psychometric properties of the Taiwan Chinese Ver-
sion of the EORTC QLQ-PR25 may be used to identify
what can and should be done for questionnaire develop-
ment. By using a clinically relevant, psychometrically
sound, and culturally appropriate assessment tool, clini-
cians can adequately and accurately assess the HRQOL
and the impacts of treatment on their patients to plan
for better treatment strategies.
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